1. Spain Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Grifols, S.A.

Grifols, S.A.

GIFOF
Grifols, S.A.US flagOther OTC
8.85
USD
- -
- -
8.70BMarket Cap
Grifols, S.A.
GIFOF
(Other OTC)

Recent

price

8.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.83
5.83
3.82
4.03
4.9
5.74
5.93
6.31
6.55
7.44
7.79
7.24
8.92
9.7
10.61
11.06
10.91
Revenue per Share
0.45
0.16
0.37
0.51
0.69
0.78
0.8
0.97
0.87
0.91
0.9
0.28
0.27
0.06
0.23
0.59
0.44
Basic EPS, GAAP
- -
0.2
0.5
0.62
1.01
0.26
0.38
0.76
0.63
0.23
1.09
0.41
-0.58
-0.14
0.78
0.92
1.4
Free Cash Flow per Basic Share
0.11
- -
- -
0.1
0.23
0.32
0.32
0.32
0.41
0.35
0.17
0.38
- -
- -
- -
0.19
- -
Dividend per Share
0.86
0.55
0.55
0.58
0.74
0.78
0.79
0.96
0.85
0.89
1.08
0.45
0.18
0.24
0.41
0.62
0.43
Book Value per Share
1.7
-4.02
-1.4
-0.98
-2.31
-2.03
-1.63
-3.25
-2.77
-0.14
-0.25
-0.81
-2.92
-3.12
-2.54
-2.88
-2.93
Tangible Book Value per Share
259
308
685
681
685
685
683
684
685
685
686
682
680
680
680
681
682
Basic Weighted Avg Shares
991
1,796
2,621
2,742
3,355
3,935
4,050
4,318
4,487
5,099
5,340
4,933
6,064
6,592
7,212
7,524
7,446
Sales/Revenue/Turnover
21.16
15.53
25.18
26.85
25.56
24.66
23.2
23.24
22.16
22.01
18.26
11.4
11.2
10.89
16.01
16.63
17.8
Operating Margin (%)
46
91
129
128
189
190
202
215
229
302
322
360
411
446
438
450
437
Depreciation Expense
116
50
257
346
470
532
545
663
597
625
619
189
185
42
157
402
298
Net Income, GAAP
26.95
37.23
34.17
31.25
20.79
23.01
23.6
4.95
18.11
20.62
19.31
24.29
26.66
20.87
52.03
18.7
37.66
Effective Tax Rate (%)
11.66
2.8
9.79
12.6
14.01
13.52
13.47
15.35
13.3
12.26
11.58
3.83
3.05
0.64
2.18
5.34
4
Profit Margin (%)
721
1,283
1,342
1,424
1,833
2,036
2,051
1,967
2,226
3,996
1,830
2,036
2,671
3,806
3,572
3,055
3,256
Working Capital
665
2,809
2,586
2,438
4,072
4,572
4,681
5,878
6,021
6,786
6,592
6,930
9,069
9,985
9,445
9,043
8,425
LT Debt
707
1,665
1,881
2,107
2,663
3,301
3,728
3,634
4,697
6,846
6,720
7,317
7,976
7,514
8,606
7,603
7,598
Total Equity
10.32
5.64
9.35
10.7
11.52
9.9
8.58
10.42
7.99
7.22
5.7
2.81
2.9
3.14
2.97
5.65
5.48
Return on Invested Capital (%)
13.3
7.46
13.64
15.91
16.19
14.06
13.44
14.89
11.97
10.22
7.45
2.8
3.79
2.58
2.95
6.07
4.03
Return on Capital (%)
62.44
25.78
94.59
89.64
104.46
102.73
101.55
110.31
96.32
105.29
91.9
36.07
86.48
29.84
71.54
115.35
57.56
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'21
Mar'25
Jun'25
ST Debt
900
- -
394
LT Borrowings
5,968
- -
7,448
LT Finance Leases
738
- -
978
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
679
- -
680
Market Capitalization
10,342
5,307
5,100

Working Capital

FRC

•

in mil. unless spec.
Jun'21
Mar'25
Jun'25
Total Current Assets
3,240
- -
5,246
Cash, Cash Equivalents & STI
408
- -
566
Accounts Receivable, Net
532
- -
749
Inventories
2,124
- -
3,347
Total Current Liabilities
1,921
- -
1,990
Payables & Accruals
787
- -
1,181
ST Debt
900
- -
394
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.85%
3%
-11.65%
Free Cash Flow
-58.67%
-206.15%
17.74%
Net Income, GAAP
29.89%
56.22%
156.05%
Sales/Revenue/Turnover
6.96%
7.55%
4.33%
Total Cash Common Dividend
- -
- -
12,700%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,818
1,793
1,976
- -
7,212
2025
1,786
1,891
1,982
- -
7,524
2026
1,700
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.08
0.1
- -
0.23
2025
0.09
0.17
- -
- -
0.59
2026
0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.19
2026
- -
- -
- -
- -
- -
Similar Companies
Sanofi Consumer Healthcare India Ltd. (SANOFICONR.NS)
AstraZeneca PLC (AZNCF)
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS)
Bayer AG (BAYRY)
Psyence Group Inc. (PSYG.CN)
Zhejiang Int'l Group Co.,Ltd. (000411.SZ)
Business
Grifols, S.A. (NASDAQ: GIFOF; BME: GRF) develops, manufactures, and markets plasma-derived medicines, transfusion medicine solutions, and biopharmaceutical products worldwide. The company produces a broad portfolio of therapies including immunoglobulins such as Flebogamma and Gammagard, albumin products like Albutein, alpha-1 antitrypsin (A1PI) under Prolastin and Zemaira brands, factor VIII (FVIII) clotting factors such as Alphanate, and other plasma protein therapeutics including Prothrombin Complex Concentrate (PCC) and antithrombin; it also offers transfusion diagnostic equipment and reagents through the Diagnostics division, including NAT screening assays, blood typing systems, and automation platforms like the WADiana MiDas; additionally, the Bio Supplies division provides contract manufacturing services, biological APIs, and reagents for biopharma customers. Grifols operates in over 110 countries, with principal manufacturing facilities in Spain, the United States (including North Carolina plasma fractionation centers), Ireland, and Mexico, targeting hospitals, clinics, governments, and biopharma companies in the healthcare and life sciences sectors. Founded in 1909 and headquartered in Barcelona, Spain, the company expanded its footprint through the 2023 acquisition of Haema, enhancing its European plasma collection network, and in 2024 announced a strategic refinancing of its debt structure amid ongoing operational optimizations in its U.S. plasma centers following prior divestiture efforts of non-core diagnostics assets.

Company News

APIChat

  • seekingalpha.com

    Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript